SELLAS Life Sciences
28 hedge funds and large institutions have $4.54M invested in SELLAS Life Sciences in 2023 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 2 closing their positions.
8,676% more call options, than puts
Call options by funds: $2.98M | Put options by funds: $34K
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
12% more funds holding
Funds holding: 25 → 28 (+3)
1.27% less ownership
Funds ownership: 11.03% → 9.76% (-1.3%)
8% less capital invested
Capital invested by funds: $4.91M → $4.54M (-$370K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$142K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$86.7K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$75K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$52K |
| 5 |
VF
Virtu Financial
New York
|
+$29.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$962K |
| 2 |
Morgan Stanley
New York
|
-$9.46K |
| 3 |
PFG
Prosperity Financial Group
San Ramon,
California
|
-$7.89K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$4.99K |
| 5 |
BlackRock
New York
|
-$4.37K |
SLS Hedge Fund Activity: Q3 2023 in Review
28 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in SELLAS Life Sciences (SLS) for Q3 2023, worth a combined $4.54M — down 7.5% from $4.91M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new SLS positions and 2 closed out — a net gain of 3 holders — while 9 added to existing stakes and 6 trimmed.
The largest buyer was Vanguard Group, adding an estimated $142K. The largest seller was Alyeska Investment Group, cutting an estimated $962K.
- 28 institutional investors held SELLAS Life Sciences (SLS) as of Q3 2023, up from 25 in Q2 2023.
- Funds reported $4.54M of SELLAS Life Sciences stock for Q3 2023, down 7.5% quarter-over-quarter.
- 5 funds opened new SELLAS Life Sciences positions in Q3 2023 and 2 closed out, a net change of +3 holders.
- The largest SELLAS Life Sciences buyer in Q3 2023 was Vanguard Group, an estimated $142K added.
- The largest SELLAS Life Sciences seller in Q3 2023 was Alyeska Investment Group, an estimated $962K sold.
Based on aggregated 13F filings for Q3 2023.